RestatementCompany-reported
What was reported
EDEN PRAIRIE, Minn. – May 22, 2026 – NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced that it plans to amend and restate its financial statements included in its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed on May 12, 2026 (the “Form 10-Q”).U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 22, 2026 · Open the source ↗
What the evidence supports
NeuroOne Medical told the SEC (Form 8-K, Item 4.02) that some previously issued financial statements should no longer be relied on. The filing gives May 21, 2026 as the date of the earliest event reported. The company also furnished a press release, which is its own account rather than a regulatory statement.
What remains unknown
The final size of any correction, which is only known once restated statements are filed.
Figures as stated
Numbers exactly as written in the source. We don’t annualise, convert or add them up.
| Figure | In context |
|---|---|
| $10.5 million | ““Our operations remain strong, our growth strategy is unchanged, and we continue to anticipate product revenue for fiscal 2026 of at least $10.5 million.”” Mentions: revenue |
| $0.5 million | “The restatement corrects a one-time revenue overstatement of approximately $0.5 million against initially reported revenue of $2.4 million for the quarter.” Mentions: revenue |
| $2.4 million | “The restatement corrects a one-time revenue overstatement of approximately $0.5 million against initially reported revenue of $2.4 million for the quarter.” Mentions: revenue |
| $0.3 million | “As a result, gross profit was overstated by approximately $0.3 million and operating loss and net loss were understated by approximately $0.3 million for the three months ended March 31, 2026.” Mentions: net loss |
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Press release headlineNeuroOne® Medical Technologies Announces Restatement of Financial Results for Quarter Ending March 31, 2026U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 22, 2026 · Open the source ↗
Press release lead paragraphEDEN PRAIRIE, Minn. – May 22, 2026 – NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced that it plans to amend and restate its financial statements included in its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed on May 12, 2026 (the “Form 10-Q”).U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 22, 2026 · Open the source ↗
Amount stated in press release“Our operations remain strong, our growth strategy is unchanged, and we continue to anticipate product revenue for fiscal 2026 of at least $10.5 million.”U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 22, 2026 · Open the source ↗
Amount stated in press releaseThe restatement corrects a one-time revenue overstatement of approximately $0.5 million against initially reported revenue of $2.4 million for the quarter.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 22, 2026 · Open the source ↗
Amount stated in press releaseAs a result, gross profit was overstated by approximately $0.3 million and operating loss and net loss were understated by approximately $0.3 million for the three months ended March 31, 2026.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 22, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:52 UTC
NeuroOne® Medical Technologies Announces Restatement of Financial Results for Quarter Ending March 31, 2026
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.